ConsulTech Logo


EU: Innovative Medicines Initiative 2 (IMI2) - 15. Call

This call is open to submit project applications in following topics:

• Integrated research platforms enabling patient-centric drug development
• Blockchain enabled healthcare
• Microenvironment imposed signatures in tissue and liquid biopsies in immune-mediated diseases
• Emerging translational safety technologies and tools for interrogating human immuno-biology
• Development and validation of translational platforms in support of synaptopathy drug discovery
• Digital endpoints in neurodegenerative and immune-mediated diseases
• AMR Accelerator Pillar A: Capability Building Network to accelerate and validate scientific discoveries
• AMR Accelerator Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic
Read More…

GLIOMARK1 clinical study successfully completed

The GLIOMARK consortium is delighted to announce that the Gliomark1 Phase II clinical study has been successfully completed. Read More…